Abstract: Tagtociclib (PF-07104091) is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor currently under clinical investigation for the treatment of advanced solid tumors, including epithelial ovarian cancer. By selectively targeting the CDK2/cyclin E complex, PF-07104091 prevents the phosphorylation of the retinoblastoma (Rb) protein, thereby halting the unregulated G1-S phase transition characteristic of many malignancies. Early-phase clinical trials have demonstrated its rapid absorption, dose-proportional plasma exposure, and preliminary antitumor activity, alongside a manageable safety profile. In the context of ovarian cancer, where alterations such as CCNE1 amplification and Cyclin E1 mutations are prevalent, PF-07104091 represents a promising targeted therapeutic approach. Ongoing research is focused on evaluating its efficacy as a monotherapy in ovarian cancer expansion cohorts, as well as exploring rational combination strategies and predictive biomarkers to overcome potential resistance mechanisms.
1. Introduction
Cyclin-dependent kinase 2 (CDK2) plays a critical role in regulating the cell cycle, specifically enforcing the transition from the G1 phase to the synthesis (S) phase[1]. In many cancers, the CDK2 gene itself is not mutated; rather, its protein signaling activity is aberrantly increased due to interactions with overexpressed cyclins, such as cyclin E or cyclin A[1]. This overactivation leads to genomic instability and unregulated cell proliferation. In epithelial ovarian cancer, particularly high-grade serous and platinum-resistant subtypes, abnormal CDK2 activity is frequently driven by cyclin E1 (CCNE1) overexpression or mutation, making CDK2 an attractive therapeutic target[1].
Tagtociclib, also known as PF-07104091, is a novel, selective CDK2 inhibitor developed by Pfizer[1]. It has entered clinical development to address malignancies driven by CDK2 dysregulation. Current clinical trials are evaluating PF-07104091 in patients with advanced or metastatic solid tumors, with a specific focus on breast and ovarian cancers, aiming to establish its safety, tolerability, and preliminary efficacy[1].
2. Pharmacological Activity
The pharmacological profile of PF-07104091 has been evaluated in a first-in-human phase 1/2a clinical trial (NCT04553133) involving 35 patients with advanced or metastatic small-cell lung, breast, or ovarian cancers[1]. The drug was administered orally at doses ranging from 75 to 500 mg twice daily (BID) in 28-day cycles. Pharmacokinetic analyses revealed that PF-07104091 is rapidly absorbed, with a median time to maximum concentration (Tmax) of 0.5 to 4 hours and a mean effective half-life of approximately 2 to 3 hours[1]. Steady-state plasma exposure increased proportionally with the administered dose.
The maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) for monotherapy were established at 300 mg BID[1]. Pharmacodynamic activity was evidenced by an early trend of decreased circulating tumor DNA (ctDNA) levels between cycle 1 day 1 and cycle 1 day 15 in response-evaluable patients treated at doses of 150 mg BID or higher[1]. While detailed efficacy data for the ovarian cancer cohort is still maturing, the drug demonstrated a disease control rate of 61.5% in metastatic breast cancer patients, prompting ongoing dose expansions for patients with ovarian cancer as a monotherapy[1].
3. Molecular Mechanism of Action
The primary mechanism of action of PF-07104091 involves the selective inhibition of CDK2. Under normal physiological conditions, the tumor suppressor protein Rb regulates the G1-S checkpoint. When the CDK2/cyclin E complex phosphorylates Rb, it de-represses E2F transcription factors, which then induce the transcription of genes necessary for DNA synthesis and cell cycle progression[1]. In cancers with high cyclin E activity, excessive Rb phosphorylation leads to a premature and unregulated G1-S transition, preventing cells from repairing damaged DNA and causing genomic instability[1].
By inhibiting CDK2, PF-07104091 prevents the phosphorylation of Rb, thereby trapping E2F transcription factors and halting the cell cycle at the G1-S checkpoint[1]. This mechanism is particularly relevant for ovarian cancer, where specific molecular alterations drive CDK2 dependency. For instance, CCNE1 amplification, Cyclin E1 mutations (present in about 20% of platinum-resistant high-grade ovarian cancers), and USP28 overexpression are all associated with altered CDK2 activity in high-grade serous ovarian cancer, providing a strong mechanistic rationale for the use of PF-07104091 in this indication[1].
4. Structure-Activity Relationship (SAR)
While the specific chemical structure and detailed atomic-level structure-activity relationship (SAR) of PF-07104091 are not fully disclosed in the provided literature, its pharmacological design emphasizes high selectivity for CDK2 over other cyclin-dependent kinases[1]. Historically, early-generation CDK inhibitors (such as SNS-032 and R547) were pan-CDK inhibitors targeting multiple kinases (e.g., CDK1, CDK2, CDK4, CDK7, CDK9), which often led to narrow therapeutic windows and off-target toxicities[1].
The structural refinement in next-generation agents like PF-07104091 has achieved specific CDK2 target engagement. This selectivity translates clinically into a distinct safety and efficacy profile. Compared to multi-CDK inhibitors, highly selective CDK2 inhibitors have demonstrated better objective response rates as monotherapies, likely because their selectivity allows for greater dose intensity and more profound target inhibition without the dose-limiting off-target effects associated with broader kinase inhibition[1].
5. Current Limitations
Despite its promise, the clinical application of PF-07104091 faces several limitations, primarily related to toxicity and potential resistance mechanisms. In the phase 1 trial, 34 out of 35 patients experienced treatment-emergent adverse events (TEAEs)[1]. The most frequent adverse events included gastrointestinal toxicities such as nausea (77.1%), diarrhea (48.6%), and vomiting (48.6%), as well as fatigue (45.7%) and anemia (45.7%)[1]. Dose-limiting toxicities (DLTs) observed at higher dose levels (300–500 mg BID) included grade 3 fatigue, nausea, and anorexia[1]. The frequency and severity of these adverse events trended higher with PF-07104091 compared to some other CDK2 inhibitors, which may reflect the greater dose intensity achieved in its trials[1].
Furthermore, resistance to CDK2 inhibitors remains a significant clinical hurdle. Preclinical models suggest that resistance can emerge through the upregulation of CDK2 target proteins or due to preexisting cellular polyploidy[1]. These mechanisms highlight the limitation of using PF-07104091 strictly as a monotherapy in broader, unselected patient populations.
6. Future Perspectives
The future development of PF-07104091 in epithelial ovarian cancer and other solid tumors relies heavily on biomarker-driven patient selection and rational combination therapies. Because the overall response rate to selective CDK2 inhibitors can be modest in unselected populations, identifying predictive biomarkers is crucial. Potential biomarkers for future investigation include CCNE1 amplification, cyclin E1/2 overexpression, Cyclin E1 mutations, and USP28 overexpression, all of which are highly relevant to ovarian cancer pathogenesis[1].
To overcome resistance and enhance efficacy, combination strategies are actively being explored. Preclinical evidence suggests that CDK2 inhibitors can induce sustained tumor regression in ovarian cancer models when paired with cytotoxic chemotherapy (e.g., carboplatin, gemcitabine) or PARP inhibitors (e.g., olaparib)[1]. Additionally, because CDK2 signaling is a known mechanism of resistance to CDK4/6 inhibitors, combining PF-07104091 with CDK4/6 inhibitors (such as PF-07220060) and endocrine therapies is currently under investigation in ongoing clinical trials[1]. These combination approaches hold significant promise for expanding the therapeutic utility of PF-07104091 in oncology.
